What is BPC-157 best supported for?

The gastrointestinal work, which is the oldest thread and the one that reached clinical development as PL-14736 for inflammatory bowel disease.

Is there a clinical result?

No. The Phase 1 record has not been updated and the Phase 2 trial has not completed; primary completion is due February 2027.

How does it compare to the other compounds here?

It has the most clinical development and one of the weakest mechanistic pictures, which is an unusual combination.

BPC-157 Studied Effects: What the Evidence Shows

The short answer

Reported effects span gastrointestinal lesion and fistula models, tendon and ligament repair, vascular effects and more. Nearly all are rat models from one research group. Clinical development occurred as PL-14736 for inflammatory bowel disease, and a Phase 2 is recruiting.

Key facts

Gastrointestinal: Lesion and fistula models
Musculoskeletal: Tendon, ligament, muscle
Vascular: Angiogenesis, blood vessel effects
Clinical: PL-14736 for IBD; Phase 2 recruiting
Dominant model: Rat
Receptor: None identified

Sorted by how well established

Best supported: the gastrointestinal work, which is the oldest thread, the closest to the compound's proposed origin, and the one that reached clinical development as PL-14736. Then the musculoskeletal work, with two studies in the Journal of Orthopaedic Research and a human trial now testing it. Then the vascular findings, which may underlie the others. Least supported: the broader claims that follow from breadth rather than from any specific study.

The gastrointestinal thread

Lesion models and fistula healing recur throughout, and Sikirić and colleagues reported on fistula healing in Current Pharmaceutical Design in 2020. This is the thread that made it to human trials for inflammatory bowel disease, reported in Inflammopharmacology in 2006, which makes it the most developed line of evidence the compound has.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

The musculoskeletal thread

Krivic 2006 on Achilles detachment and Cerovecki 2010 on ligament healing, both in the Journal of Orthopaedic Research. This is the thread the current Phase 2 trial tests, in acute hamstring muscle strain, meaning a preclinical line is about to meet a randomised placebo-controlled human endpoint.

What is absent

A molecular target. Substantial independent replication outside the Zagreb group. And any reported clinical result: the Phase 1 record has not been updated and the Phase 2 has not completed. None of these absences refutes the preclinical findings; together they mark the boundary of what can be said.

How it compares within this library

BPC-157 has the most clinical development of any compound in these categories, and one of the weaker mechanistic pictures. DSIP has neither. GHK-Cu has better-defined chemistry and no clinical programme. TB-500 has a clearer molecular function and no trials. That combination of real clinical progress on an unmapped mechanism is unusual.

Frequently asked questions

What is BPC-157 best supported for?: The gastrointestinal work, which is the oldest thread and the one that reached clinical development as PL-14736 for inflammatory bowel disease.
Is there a clinical result?: No. The Phase 1 record has not been updated and the Phase 2 trial has not completed; primary completion is due February 2027.
How does it compare to the other compounds here?: It has the most clinical development and one of the weakest mechanistic pictures, which is an unusual combination.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

BPC-157 Studied Effects, Sorted by Evidence